• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary pharmacology & therapeutics >What's in the pipeline? Prospects for monoclonal antibodies (mAbs) as therapies for lung diseases.
【24h】

What's in the pipeline? Prospects for monoclonal antibodies (mAbs) as therapies for lung diseases.

机译：正在准备什么？单克隆抗体（mAbs）作为治疗肺部疾病的前景。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The striking clinical results from recent studies with Remicade (infliximab, a monoclonal anti-TNFalpha antibody) in rheumatoid arthritis, Crohn's disease and psoriasis demonstrate the disease-altering potential of monoclonal antibodies (mAbs) in chronic inflammation. Chronic obstructive pulmonary disease (COPD) and asthma represent two major chronic pulmonary inflammatory diseases with substantial unmet medical needs. Most of the cells and mediators implicated in the pathophysiology of COPD and asthma are excellent targets for mAb intervention. Indeed, clinical trials with mAbs directed against IL-5, IgE, and CD4 yielded results that are critical in dissecting the pathophysiology of asthma, and reinforce the potential for mAbs as therapeutic agents in treating pulmonary diseases. Furthermore, fundamental advances in the discovery, manufacture and safety of mAbs underscore the enormous therapeutic value of these agents for chronic pulmonary diseases. Indeed, a large number of mAbs are in pre-clinical and clinical development for treating these conditions. In this review, we discuss the scientific rationale for generating mAb therapies directed specifically toward COPD and asthma. We believe that as a therapeutic class, mAbs offer the opportunity to alter symptoms, progression and outcome of chronic pulmonary diseases.
机译：最近对雷米卡德（英夫利昔单抗，一种单克隆抗TNFα抗体）在类风湿性关节炎，克罗恩病和牛皮癣中的研究取得了惊人的临床结果，证明了单克隆抗体（mAbs）在慢性炎症中具有改变疾病的潜力。慢性阻塞性肺疾病（COPD）和哮喘是两种主要的慢性肺炎性疾病，其医疗需求尚未得到满足。与COPD和哮喘的病理生理有关的大多数细胞和介质是mAb干预的极好的靶标。实际上，针对IL-5，IgE和CD4的mAb的临床试验得出的结果对于剖析哮喘的病理生理学至关重要，并增强了mAb作为治疗肺部疾病的治疗剂的潜力。此外，mAb的发现，制造和安全性方面的基础性进步突显了这些药物对慢性肺部疾病的巨大治疗价值。实际上，大量mAb处于临床前和临床开发中，用于治疗这些疾病。在这篇综述中，我们讨论了产生专门针对COPD和哮喘的mAb治疗的科学原理。我们认为，作为治疗类，单克隆抗体提供了改变慢性肺部疾病的症状，进展和结果的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号